Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sFRP3 siRNA
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
sFRP3 siRNA is a small interfering RNA designed to silence the expression of the *FRZB* gene, which encodes Secreted Frizzled-Related Protein 3 (sFRP3). sFRP3 is a member of the sFRP family that typically acts as a modulator of Wnt signaling by binding directly to Wnt proteins. While often considered a tumor suppressor in some contexts, research in renal cell carcinoma (RCC) has indicated that sFRP3 may play an oncogenic role in metastatic progression. Treatment with sFRP3 siRNA in metastatic RCC cell lines has been shown to decrease cell viability and invasiveness, potentially by downregulating downstream effectors like MMP-3 and ANGPT1. This agent is primarily used as a research tool to investigate the role of Wnt signaling components in cancer biology.
- Other names
- FRZB siRNAsecreted frizzled-related protein 3 siRNA
02
Targets
sFRP3 (Secreted frizzled-related protein 3)
Beyond the preview
Go deeper on sFRP3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sFRP3 siRNA.